Severe heatwave conditions are forecast in NSW in the coming days. Read more
Event date and time: Tuesday, 12 December 2023, 6.00 pm – 8.00 pm
Event venue: Online
Registration: Registrations via the event website.
For decades Respiratory Syncytial Virus (RSV) has been established as a leading cause of infant bronchiolitis and pneumonia hospitalisations but why is it only now coming into the public spotlight? Sanofi is hosting an online webinar to help understand why there has been recent interest in RSV and the importance of protecting all infants from RSV disease.
The scope of this fully virtual 2-hour educational webinar includes exciting topics such as burden of disease across Australia. A leading Australian RSV epidemiologist will highlight the high unmet need for RSV prevention in Australian neonates and infants and answer the key question of why all infants should be protected. In addition, the Sanofi RSV medical lead will outline the clinical trial development for strategies designed to reduce RSV disease in the general infant population.
Relevant for all Australian health care professionals in the primary care setting (GPs, nurses) as well as specialists such as paediatricians, neonatologists, midwives and any HCP with an interest in RSV and infectious disease prevention in infants. This webinar will provide fresh knowledge about clinical trial data for RSV prevention. With plenty of time for audience participation through Q&A, the webinar will end with an interactive 30 mins dedicated panel discussion with all speakers.
Contact Email: adrian.widjonarko@sanofi.com
